By taking these factors together, we concluded that our simple and cancer-favoring strategic virus design of the CVV eradicates metastatic CD44-expressing cells, provided that our CVV may be a promising therapeutic reagent that targets metastatic liver cancer cells. Here, CD44 is linked to cancer.